Ranbaxy inks in-license pact with Eurodrug Lab

Mumbai, May 17: Pharma major Ranbaxy Laboratories Ltd, has entered into an in-licensing agreement with the Netherlands-based Eurodrug Laboratories for Doxophylline, a new asthma drug to be launched in India for the first time.

In a communique to the Bombay Stock Exchange (BSE), Ranbaxy informed that the product developed in collaboration with many European medical centers, will be introduced in India under the brand name 'Synasma'.

The drug is indicated for chronic bronchitis, asthma and chronic obstructive pulmonary disease (COPD) and is considered to be superior to available Xanthine analogues like Theophylline and Aminophylline.

The release further stated that Eurodrug has been successfully marketing this medicine in Europe, Latin America and a few Asian markets like Korea, Philippines and Thailand.

Commenting on the development, Ranbaxy's Regional Director, India and Middle East, Sanjeev I Dani, said that ''Synasma is yet another innovative asthma drug to be introduced in India for the first time by Ranbaxy.'' It is our strategic intent to in-licence differentiated products for the Indian market in the post-patent era and this drug augments our position in the fast-growing asthma segment, he added.

UNI